PitchBook clients can access this report’s Excel data pack via the Research Center on the PitchBook Platform.
Healthtech faces an uneven recovery as headwinds persist
Healthtech shares broadly underperformed major market indexes in Q3 as the sector remained volatile. The electronic health records & clinical information segment was particularly hard hit, down 11% on average YTD. In the virtual care & remote patient monitoring segment, which has seen significant valuation pressure since the pandemic era, recent entrants Hinge Health and Omada outperformed by a wide margin, signaling strong investor appetite for recent VC-backed listings. Other healthtech standouts included iRhythm Technologies, up 92% YTD, Doximity, up 37%, and Sectra, up 30%.
Elsewhere in the market, individual moves underscored the sector’s volatility. Claritev has surged more than 300% YTD after exceeding Q2 revenue expectations, though its valuation remains far below its 2021 peak—illustrating the significant healthtech repricing over the past four years. Hims & Hers Health extended its volatile run, climbing 125% YTD as weight-loss drug demand remained robust despite the collapse of its Novo Nordisk partnership and ongoing US Food and Drug Administration scrutiny of compounded GLP-1s.
Our Q3 2025 Healthtech Public Comp Sheet and Valuation Guide tracks metrics for key publicly traded companies that include stock performance, changes in valuation, historical valuations, revenue growth, EBITDA growth, and EBITDA margins. It is constructed using the PitchBook Excel plugin available to subscribers.